21.482 articles found

Determination of the motor status of patients with advanced Parkinson's disease under levodopa-carbidopa intestinal gel using a machine learning model.

Efthymiopoulou E, Antonoglou A, Loupo B, Bougea A.

Acta Neurol Belg · 2022-12-06

DOI: 10.1007/s13760-022-02156-zPMID: 36472797

Advances in Gene Therapy Techniques to Treat <i>LRRK2</i> Gene Mutation.

Chung SK, Lee SY.

Biomolecules · 2022-12-05

DOI: 10.3390/biom12121814PMID: 36551242

Microbiome and Metabolome Insights into the Role of the Gastrointestinal-Brain Axis in Parkinson's and Alzheimer's Disease: Unveiling Potential Therapeutic Targets.

Zacharias HU, Kaleta C, Cossais F, Schaeffer E, Berndt H, Best L, Dost T, Glüsing S, Groussin M, Poyet M, Heinzel S, Bang C, Siebert L, Demetrowitsch T, Leypoldt F, Adelung R, Bartsch T, Bosy-Westphal A, Schwarz K, Berg D.

Metabolites · 2022-12-05

DOI: 10.3390/metabo12121222PMID: 36557259

The Pathology of Primary Familial Brain Calcification: Implications for Treatment.

Xu X, Sun H, Luo J, Cheng X, Lv W, Luo W, Chen WJ, Xiong ZQ, Liu JY.

Neurosci Bull · 2022-12-05

DOI: 10.1007/s12264-022-00980-0PMID: 36469195

Toll-like receptors and NLRP3 inflammasome-dependent pathways in Parkinson's disease: mechanisms and therapeutic implications.

Soraci L, Gambuzza ME, Biscetti L, Laganà P, Lo Russo C, Buda A, Barresi G, Corsonello A, Lattanzio F, Lorello G, Filippelli G, Marino S.

J Neurol · 2022-12-03

DOI: 10.1007/s00415-022-11491-3PMID: 36460875

In Silico Evaluation and In Vitro Determination of Neuroprotective and MAO-B Inhibitory Effects of Pyrrole-Based Hydrazones: A Therapeutic Approach to Parkinson's Disease.

Kondeva-Burdina M, Mateev E, Angelov B, Tzankova V, Georgieva M.

Molecules · 2022-12-02

DOI: 10.3390/molecules27238485PMID: 36500572

Vitamin D3 actions on astrocyte cells: A target for therapeutic strategy in Parkinson's disease?

de Siqueira EA, Magalhães EP, de Menezes RRPPB, Sampaio TL, Lima DB, da Silva Martins C, Neves KRT, de Castro Brito GA, Martins AMC, de Barros Viana GS.

Neurosci Lett · 2022-12-02

DOI: 10.1016/j.neulet.2022.136997PMID: 36470505

Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease

Goyal A, Verma A, Dubey N, Raghav J, Agrawal A.

Journal of food biochemistry · 2022-12-01

Advantages of Rho-associated kinases and their inhibitor fasudil for the treatment of neurodegenerative diseases.

Wang Q, Song LJ, Ding ZB, Chai Z, Yu JZ, Xiao BG, Ma CG.

Neural Regen Res · 2022-12-01

DOI: 10.4103/1673-5374.335827PMID: 35662192

[Erratum to: Implementation of an individualized tablet-based training program in the domestic setting following complex treatment of Parkinson's disease-success factors and barriers].

Wagner L, Deck R.

Nervenarzt · 2022-12-01

DOI: 10.1007/s00115-022-01368-1PMID: 35939117

Timing of Physical Therapy Sessions for Individuals With Parkinson Disease May Unlock Benefits.

Salloum RG, Au KLK, Okun MS.

JAMA Neurol · 2022-12-01

DOI: 10.1001/jamaneurol.2022.2649PMID: 36094521

Evaluation of Simvastatin as a Disease-Modifying Treatment for Patients With Parkinson Disease: A Randomized Clinical Trial.

Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, Jones B, Chapman R, Cocking L, Wilks J, Webb D, Carroll C, PD STAT Study Group.

JAMA Neurol · 2022-12-01

DOI: 10.1001/jamaneurol.2022.3718PMID: 36315128